These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 30530971

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I, Illán-Gala I, Alcolea D, Sánchez-Saudinós MB, Salgado SA, Morenas-Rodríguez E, Subirana A, Videla L, Clarimón J, Carmona-Iragui M, Ribosa-Nogué R, Blesa R, Fortea J, Lleó A.
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [Abstract] [Full Text] [Related]

  • 3. Associations Between Free and Cued Selective Reminding Test and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment.
    Giuffrè GM, Quaranta D, Citro S, Morganti TG, Martellacci N, Vita MG, Rossini PM, Calabresi P, Marra C.
    J Alzheimers Dis; 2024; 100(2):713-723. PubMed ID: 38905044
    [Abstract] [Full Text] [Related]

  • 4. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P, Passerini G, Falautano M, Comi G, Magnani G.
    J Alzheimers Dis; 2016 Oct 18; 54(4):1495-1508. PubMed ID: 27589522
    [Abstract] [Full Text] [Related]

  • 5. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J.
    Exp Gerontol; 2017 Dec 15; 100():45-53. PubMed ID: 29054536
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 15; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J, Verhülsdonk S, Pessanha F, Menge T, Seitz RJ, Kujovic M, Höft B, Supprian T, Lange-Asschenfeldt C.
    J Alzheimers Dis; 2019 Jan 15; 72(4):1119-1127. PubMed ID: 31683478
    [Abstract] [Full Text] [Related]

  • 13. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
    Marizzoni M, Ferrari C, Macis A, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Pizzini F, Rossini PM, Salvatore M, Schönknecht P, Soricelli A, Del Percio C, Hensch T, Hegerl U, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB, PharmaCog Consortium.
    J Alzheimers Dis; 2019 Jan 15; 69(1):49-58. PubMed ID: 30958351
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB, Giedraitis V, Cedervall Y, Lennhed B, Berglund L, McKee K, Kilander L, Rosendahl E, Ingelsson M, Åberg AC.
    J Alzheimers Dis; 2019 Jan 15; 71(s1):S75-S83. PubMed ID: 31104024
    [Abstract] [Full Text] [Related]

  • 16. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ.
    J Alzheimers Dis; 2017 Jan 15; 60(3):1119-1128. PubMed ID: 28984585
    [Abstract] [Full Text] [Related]

  • 17. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD.
    Bruno D, Gleason CE, Koscik RL, Pomara N, Zetterberg H, Blennow K, Johnson SC.
    Int J Geriatr Psychiatry; 2019 Mar 15; 34(3):415-419. PubMed ID: 30430632
    [Abstract] [Full Text] [Related]

  • 18. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH, Cogo-Moreira H, Rabin JS, Black SE, Swardfager W, Alzheimer's Disease Neuroimaging Initiative.
    J Neurosci; 2019 Sep 11; 39(37):7428-7437. PubMed ID: 31350262
    [Abstract] [Full Text] [Related]

  • 19. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.
    J Alzheimers Dis; 2015 Sep 11; 44(2):625-33. PubMed ID: 25322924
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Sep 11; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.